Risk Factors Analysis of Thromboembolism in Patients with Lymphoma Chemotherapy.
10.19746/j.cnki.issn.1009-2137.2022.01.021
- Author:
Xiao LI
1
;
Shu-Ling HOU
2
;
Xi LI
3
;
Li LI
3
;
Ke LIAN
3
;
Ju-Ya CUI
3
;
Gang-Gang WANG
3
;
Tao YANG
4
Author Information
1. Department of Lymphatic Oncology, Bethune Hospital Affiliated to Shanxi Medical University Taiyuan 030000, Shanxi Province, China.
2. Department of Lymphatic Oncology, Shanxi Bethune Hospital Taiyuan 030000, Shanxi Province, China,E-mail: 13834134457@139.com.
3. Department of Lymphatic Oncology, Shanxi Bethune Hospital Taiyuan 030000, Shanxi Province, China.
4. Department of Vascular Surgery, Shanxi Bethune Hospital Taiyuan 030000, Shanxi Province, China.
- Publication Type:Journal Article
- Keywords:
lymphoma;
chemotherapy;
risk factor;
thromboembolism
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
Female;
Humans;
Lymphoma/drug therapy*;
Middle Aged;
Prognosis;
Retrospective Studies;
Risk Factors;
Thromboembolism/epidemiology*
- From:
Journal of Experimental Hematology
2022;30(1):131-135
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the risk factors affecting thromboembolism in lymphoma patients with chemotherapy.
METHODS:Three hundred and four consecutive lymphoma patients treated by chemotherapy between January 2012 and July 2019 were enrolled and retrospectively analyzed, consisting of 111 patients with thromboembolism and 193 without thromboembolism. Univariate analysis was used to compare the clinical characteristics and related laboratory examination between the patients, while multivariate Logistic regression analysis were used to identify the risk factors affecting thromboembolism in lymphoma patients with chemotherapy.
RESULTS:Univariate analysis showed that the female, BMI <18.5 or >24, ≥60 years old, with abnormal platelets before chemotherapy, prolonged single hospitalization days and patients at Ann Arbor stage III and IV could increase the incidence of thromboembolism in lymphoma patients treated by chemotherapy. Multivariate Logistic regression analysis showed that abnormal platelet count before chemotherapy, patients at Ann Arbor stage III and IV, and female were all the independent risk factors affecting thromboembolism in lymphoma patients thromboembolism after chemotherapy (P<0.05).
CONCLUSION:For lymphoma chemotherapy patients, female, abnormal platelet count before chemotherapy and Ann Arbor stages III and IV show a significantly higher risk for thromboembolism. Thus, preventive anticoagulation therapy is recommended.
